


**[For Immediate Release]**



## **TUL's Products Acquired International Standard Accreditation Once Again Granted EU Certificate of Suitability**

(23 March 2009 – Hong Kong) – The United Laboratories International Holdings Limited ("TUL" or the "Group"; Stock code: 3933), one of the leading pharmaceutical companies in the PRC, is pleased to announce that the European Directorate for the Quality of Medicines ("EDQM") issued a Certificate of Suitability ("COS") to acknowledge Amoxicillin Compacted. Following a COS granted for TUL's Amoxicillin Powder in November 2007, the Group once again obtained the COS, and is currently the only pharmaceutical companies in the PRC with the certificates for both types of Amoxicillin products, which is a tribute to TUL's excellent product quality and undoubtedly high safety standards.

The COS is a testament of quality control of the bulk medicine listed in European Pharmacopeia. It has been deemed as another legitimate way for the registration of PRC bulk medicine by EU finished product manufacturers. COS is well recognized by more than 30 member states of European Pharmacopeia. The COS for acknowledgment of TUL's Amoxicillin Compacted is mainly used for European human drug market, where the market capacity is larger than that of Amoxicillin Powder. With the certificates, it is expected to gain more customers from European Union areas, thereby further pushing the Group's export business forward.

Mr. Choy Kam Lok, Chairman of TUL said, "Following the COS granted to the Group's Amoxicillin Powder last year, the Group has once again secured a certificate for Amoxicillin Compacted, indicating that the high quality of TUL's products has won further international recognition. This will not only help TUL to further expand in Europe and increase its market share there but also boost consumers' confidence of the group's product safety. Amoxicillin has always been one of TUL's major products. With the Group's well-established 6-APA production and supply facilities, we can undertake the upstream production of intermediate products, the mid-stream processing of intermediate products into bulk medicine as well as the downstream production of antibiotics finished products from bulk medicine. This highly vertically integrated production model enables the Group to enhance and take full control of Amoxicillin's excellent quality. In the future, we will continue to maintain our product quality and safety so as to safeguard our leading position in the pharmaceutical industry."

*-END-*

### **Company Background**

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 31 December 2008, the Group has a total of 162 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 40 bulk medicines and 122 finished products.

For further enquiries, please contact  
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau  
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952  
Fax: (852) 3170 6606  
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/  
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com